Get to know our clinical trials
Clinical trial to evaluate the safety and efficacy of new interventions and study combinations in participants with colorectal cancer.
THE OBJECTIVE OF THIS STUDY IS TO LEARN MORE ABOUT THE EFFECTIVENESS AND SAFETY OF THE STUDY DRUG, VOLRUSTOMIG (ALSO CALLED MEDI5752), GIVEN IN COMBINATION WITH A REFERENCE TREATMENT FOR COLORECTAL CANCER.
Technical Summary
- PHASE 2, OPEN-LABEL, MULTICENTER, MASTER PROTOCOL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NEW INTERVENTIONS AND STUDY COMBINATIONS IN PARTICIPANTS WITH COLORECTAL CANCER (CANTOR).
- Code EudraCT: 2024-518469-84
- Protocol number: D798VC00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: Volrustomig (MEDI5752)
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.